|
Activity Number:
|
115
- Novel Statistical Methods for Emerging Problems in Modern Clinical Trials and Drug Development
|
|
Type:
|
Topic Contributed
|
|
Date/Time:
|
Monday, July 29, 2019 : 8:30 AM to 10:20 AM
|
|
Sponsor:
|
Biopharmaceutical Section
|
|
Abstract #306973
|
|
|
Title:
|
Robust Clinical Trial Design and Analysis When Non-Proportional Hazards Are Likely
|
|
Author(s):
|
Keaven Anderson*
|
|
Companies:
|
Merck & Company, Inc.
|
|
Keywords:
|
clinical trials;
non-proportional hazards;
design;
weighted logrank
|
|
Abstract:
|
The Non-Proportional Hazards Working Group (NPHWG) is an industry group formed following discussions with the FDA in 2016. The group has focused on finding a testing strategy that is robust to various alternatives particularly including both proportional hazards and delayed effects. We will discuss advantages and disadvantages of a combination test approach to design and analysis. Also, we include both asymptotic and simulation tools to evaluate such designs. Finally, we contrast the robust testing approach to other approaches such as the RMST or generalized pairwise comparisons that have corresponding estimands that are easily interpretable. The robust testing approach may be particularly useful quickly progressing disease such as metastatic cancer.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2019 program
|
